The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors
Open Access
- 4 June 2013
- journal article
- research article
- Published by Springer Nature in CNS Drugs
- Vol. 27 (6) , 469-478
Abstract
Introduction Immediate-release memantine (10 mg, twice daily) is approved in the USA for moderate-to-severe Alzheimer’s disease (AD). This study evaluated the efficacy, safety, and tolerability of a higher-dose, once-daily, extended-release formulation in patients with moderate-to-severe AD concurrently taking cholinesterase inhibitors. Methods In this 24-week, double-blind, multinational study (NCT00322153), outpatients with AD (Mini-Mental State Examination scores of 3–14) were randomized to receive once-daily, 28-mg, extended-release memantine or placebo. Co-primary efficacy parameters were the baseline-to-endpoint score change on the Severe Impairment Battery (SIB) and the endpoint score on the Clinician’s Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus). The secondary efficacy parameter was the baseline-to-endpoint score change on the 19-item Alzheimer’s Disease Cooperative Study–Activities of Daily Living (ADCS–ADL19); additional parameters included the baseline-to-endpoint score changes on the Neuropsychiatric Inventory (NPI) and verbal fluency test. Data were analyzed using a two-way analysis of covariance model, except for CIBIC-Plus (Cochran–Mantel–Haenszel test). Safety and tolerability were assessed through adverse events and physical and laboratory examinations. Results A total of 677 patients were randomized to receive extended-release memantine (n = 342) or placebo (n = 335); completion rates were 79.8 and 81.2 %, respectively. At endpoint (week 24, last observation carried forward), memantine-treated patients significantly outperformed placebo-treated patients on the SIB (least squares mean difference [95 % CI] 2.6 [1.0, 4.2]; p = 0.001), CIBIC-Plus (p = 0.008), NPI (p = 0.005), and verbal fluency test (p = 0.004); the effect did not achieve significance on ADCS–ADL19 (p = 0.177). Adverse events with a frequency of ≥5.0 % that were more prevalent in the memantine group were headache (5.6 vs. 5.1 %) and diarrhea (5.0 vs. 3.9 %). Conclusion Extended-release memantine was efficacious, safe, and well tolerated in this population.Keywords
This publication has 44 references indexed in Scilit:
- Assessment of Functional Impairment in Dementia with the Spanish Version of the Activities of Daily Living QuestionnaireDementia and Geriatric Cognitive Disorders, 2009
- Memantine for the Treatment of Alzheimer???s DiseaseDrug Safety, 2008
- Safety and tolerability of once‐daily versus twice‐daily memantine: a randomised, double‐blind study in moderate to severe Alzheimer's diseaseInternational Journal of Geriatric Psychiatry, 2007
- Spanish Instrument Protocol: New Treatment Efficacy Instruments for Spanish-speaking Patients in Alzheimer Disease Clinical TrialsAlzheimer Disease & Associated Disorders, 2006
- Adherence to MedicationNew England Journal of Medicine, 2005
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJAMA, 2004
- Medication Non-Adherence in the ElderlyDrugs & Aging, 2004
- The disparate effects of Alzheimer's disease and Huntington's disease on semantic memory.Neuropsychology, 1999
- The Neuropsychiatric InventoryNeurology, 1994
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984